The July 2026 edition of the 1Cell.Ai Newsletter explores a pivotal moment in precision oncology, when emerging evidence becomes clinical practice. This issue unpacks the latest NCCN Bladder Cancer guideline update endorsing ctDNA-based minimal residual disease (MRD) testing for treatment decision-making, highlighting how molecular evidence is beginning to redefine adjuvant therapy and patient selection. For oncologists navigating the shift toward precision-guided care, this edition offers timely insights into one of the year’s most significant practice-changing developments.
The newsletter also introduces the OncoPredikt® BreastRS™ Early Access Program, showcasing an AI-powered approach to breast cancer recurrence risk assessment that delivers genomics-grade insights directly from routine H&E slides. Alongside the clinical validation data, readers will discover how this initiative aims to expand access to advanced recurrence scoring while creating new opportunities for multicentre research collaboration across India. If you’re interested in how artificial intelligence is making precision oncology more accessible, this feature is worth exploring.
Rounding out the issue is a concise review of the month’s most impactful oncology developments, from breakthrough Phase 3 trial results in lung cancer to the first overall survival success for a B7-H3 antibody-drug conjugate, alongside broader discussions on the future of precision oncology and access to innovative therapies in India. Whether you’re looking to stay ahead of evolving clinical evidence or understand the trends shaping tomorrow’s treatment landscape, this edition delivers high-value insights in one comprehensive read.